Pathos inks back-to-back cancer contracts with AstraZeneca, China's Alphamab
AI-enabled oncology biotech Pathos AI signed back-to-back cancer deals with AstraZeneca and China's Alphamab worth up to $2.2 billion.
Pathos AI
Private
AI-enabled precision oncology biotech that uses multimodal patient data, biological modeling, and machine learning to identify Phase 1 cancer drugs for specific patient subgroups, partnering with pharma for clinical trial design and drug repositioning.
Company Info
Sector:Biotechnology (AI-enabled precision oncology)
Headquarters:Chicago, Illinois, USA
Founded:2022
Website:www.pathos.com/
Funding Round:Series C
Total Funding:$62M
Recent News
Pathos Picks Up Two Cancer Drugs Poised for Clinical Development With AI Agents
Pathos AI picked up two cancer drugs poised for clinical development, applying AI agents to drive the work forward.
Leadership Team
Iker Huerga
Chief Executive Officer (since 2025)
Eric Lefkofsky
Co-Founder
Ryan Fukushima
Co-Founder
Careers & Job Openings